A 2023 retrospective cohort study found semaglutide significantly reduced binge eating episodes in patients with BED the first study of its kind A 2020 pilot study of dulaglutide found it reduced binge episodes in patients with type 2 diabetes and BED A 2026 meta-analysis found liraglutide reduced binge frequency by approximately 1.28 fewer episodes per week compared to placebo A rapid review of 25 studies encompassing over 8,700 adult patients found that binge eating episodes and prevalence reduced following liraglutide and semaglutide An observational study of 69 people with obesity found emotional eating dropped from 72.5% to 11.5% after three months of semaglutide The Critical Caveats Despite a promising early signal, these findings should be held carefully
Orforglipron (Not Yet FDA Approved) According to CNN, Eli Lilly's oral GLP-1 candidate achieved approximately 11 percent average weight loss over 72 weeks at the highest dose
Available from Accessed 29 January 2024 Garca-Sempere A, Orrico-Snchez A, Muoz-Quiles C et al (2020) Data resource profile: the Valencia health system integrated database (VID)
According to the International Diabetes Federation, there are currently 425 million diabetic patients worldwide, and it is estimated that by 2045, there will be nearly 700 million diabetic patients
Each vial contains lyophilized Glutathione, a powerful ingredient that revitalize the skins appearance and promote radiance
Vandetanib treatment produces significant side effects, including diarrhea, rash, hypertension, and QT prolongation